Baird analyst Colin Sebastian noted Zynga reported solid Q3 results which were above expectations. The analyst noted engagement trends continue to benefit from investments in live services and that margins improved while costs were cut. He said M&A remained disciplined while the company strengthened its position within its genre. Sebastian maintained his Neutral rating and $4 price target on Zynga shares.

09/15/17

BARD

09/15/17NO CHANGETarget $4BARDNeutral

Zynga turnaround remains well on track, says Baird

Baird analyst Colin Sebastian hosted meetings with Zynga management, which reinforced his constructive view on the company's turnaround strategy and its progress on improving profitability through live services. The analyst said beyond its Phase 1 turnaround strategy he sees a pathway for the company to move beyond 20% EBITDA margins. Sebastian maintained his Neutral rating and $4 price target on Zynga shares.

09/08/17

GSCO

09/08/17INITIATIONTarget $3.9GSCONeutral

Zynga initiated with a Neutral at Goldman Sachs

Goldman analyst Christopher Merwin initiated Zynga with a Neutral and a $3.90 price target saying the company must create a "hit" game in order to re-rate shares positively and said its difficult to predict the success of new mobile IP.

07/20/17

MSCO

07/20/17NO CHANGEMSCOOverweight

Morgan Stanley bullish on Zynga

Morgan Stanley analyst Brian Nowak is bullish on Zynga and positive on the Q2 report saying he expects adjusted EBITDA of $4M, 16% above consensus, and inline revenues. He expects outperformance to be driven by opex discipline and from strong performances from CSR2 and slots. Nowak believes the Zynga's strong Q1 performance was the beginning of a multi-year turnaround driven and reiterates his Overweight rating and $4.50 price target.

Boston Scientific last night confirmed speculation by announcing additional delays to its Lotus transcatheter valve program, JPMorgan analyst Michael Weinstein tells investors in a research note. The good news is that the delay is internally driven, the analyst notes after speaking to management. He points out that there are no issues at this point with the European notified body or with the FDA. The issue is manufacturing, Weinstein writes. The analyst is a buyer of Boston Scientific following yesterday's selloff. Despite the Lotus delay, he still thinks the company can grow organic sales by 6% in 2018 and 7%-8% in 2019-2020. Weinstein keeps an Overweight rating on Boston Scientific with a $31 price target.

11/29/17

COWN

11/29/17NO CHANGETarget $32COWNOutperform

Boston Scientific speculation worse than actual news, says Cowen

Cowen analyst Joshua Jennings noted Boston Scientific shares were weak yesterday prior to the company announcing another setback to the timelines for the Lotus valve system's European reintroduction and U.S. approval and launch. The analyst believes the speculation prior to the release was worse than the actual announcement and he believes there will be little effect on Q4 or 2017 guidance. However, admittedly, the 2018 impact is unknown at this time. Jennings reiterated his Outperform rating and $32 price target on Boston Scientific shares.

Wells Fargo analyst Larry Biegelsen notes that weakness in shares of Boston Scientific followed the company having canceled an investor conference appearance, pointing out that the last time this happened the company then announced a recall of its Lotus TAVR device in Europe. While he attributes the pullback to investor worries about "another shoe to drop," his checks have found no new issues with Lotus, Biegelsen tells investors. Even assuming Lotus revenues were completely removed, he sees a floor for Boston Scientific at $26-$27 per share. Biegelsen maintains an Outperform rating on Boston Scientific, which is down nearly 6% to $26.86 in afternoon trading.

PXPraxair

$156.36

4.28 (2.81%)

11/13/17

ARGS

11/13/17UPGRADETarget $171ARGSBuy

Praxair upgraded to Buy at Argus on positive impact of Linde merger

As reported earlier, Argus analyst Bill Selesky upgraded Praxair to Buy from Hold with a $171 price target. Selesky says the company is well positioned to deliver stronger EPS growth thanks to its mix of high-growth businesses driving above-industry-average margins, earnings, and returns on invested capital. The analyst adds that Praxair's strategic merger with Linde AG will allow for much greater scale and geographic reach.

11/13/17

11/13/17UPGRADE

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.M. Smucker (SJM) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic saying he believes the rout of food stocks is ebbing and since this company is the worst performing stock in his coverage universe, he chose to play the food trade with it. 2. Delek US (DK) upgraded to Strong Buy from Outperform at Raymond James with analyst Justin Jenkins saying it will benefit from a wider Brent-WTI spread. 3. Nvidia (NVDA) upgraded to Market Perform from Underperform at BMO Capital with analyst Ambrish Srivastava saying the company has demonstrated a "far stronger" data center business than he had forecast and its leverage is greater than anticipated. 4. Praxair (PX) upgraded to Buy from Hold at Argus with analyst Bill Selesky saying the company is well positioned to deliver stronger Earnings Per Share growth thanks to its mix of high-growth businesses driving above-industry-average margins, earnings, and returns on invested capital. 5. TD Ameritrade (AMTD) upgraded to Buy from Hold at Deutsche Bank with analyst Brian Bedell saying trading volumes are improving, trade pricing will hold up better than expected and the Scottrade integration is going very well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

11/17/17

JPMS

11/17/17NO CHANGETarget $172JPMSOverweight

Praxair price target raised to $172 from $156 at JPMorgan

JPMorgan analyst Jeffrey Zekauskas raised his price target for Praxair (PX) to $172 and keeps an Overweight rating on the name. The analyst estimates the combined Praxair/Linde company is currently being valued at $145 per share. Should Praxair trade at parity to Air Products (APD), the new Praxair would be worth $172 per share, Zekauskas tells investors in a research note. He believes, however, that Praxair is capable of trading at a one multiple point premium to Air Products, which he thinks could yield a higher $189 per share value.

AT&T Mobility has reached a tentative agreement with the Communications Workers of America in Mobility Orange contract negotiations. The four-year agreement, which will be submitted to the union's membership for a ratification vote in coming days, covers about 20,000 employees in 36 states and the District of Columbia - AT&T's Mobility Orange unit, which encompasses CWA Districts 1, 2-13, 4, 7 and 9.

Pfizer announced that the United States FDA has approved IXIFI, a chimeric human-murine monoclonal antibody against tumor necrosis factor, as a biosimilar to Remicade for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Western Alliance Bancorporation announced that during the first quarter of 2018 Robert Sarver will transition from Chairman and CEO to Executive Chairman. In conjunction with Sarver's change in role, Ken Vecchione will be promoted to Chief Executive Officer, Dale Gibbons to Vice Chairman and Chief Financial Officer, and James Haught to President and Chief Operating Officer, all effective April 1, 2018.

Aqua America announced that President and CEO Christopher H. Franklin has been elected chairman of the board, effective Jan. 1, 2018. Franklin became CEO in July 2015 and has served on the board of directors since October 2015. He succeeds Nicholas DeBenedictis, former CEO, who will continue to serve on the board as chairman emeritus.